Heart failure: A hemodynamic disorder complicated by maladaptive proliferative responses

Journal of Cellular and Molecular Medicine

Volumn 7, Issue 1, 2003, Pages 1-10

  Katz, Arnold M ^a,b  

^a UNIVERSITY OF CONNECTICUT HEALTH CENTER   (United States)

^b NONE   (United States)

Author keywords

ACE inhibitors; Diuretics; Heart failure; Hypertrophy; Overload; Positive inotropic agents; Remodeling; Vasodilators

Indexed keywords

ALDOSTERONE ANTAGONIST; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; FLOSEQUINAN; HYDRALAZINE; IBOPAMINE; INOTROPIC AGENT; ISOSORBIDE DINITRATE; MINOXIDIL; MOXONIDINE; NITRATE; PHOSPHODIESTERASE INHIBITOR; PROSTACYCLIN DERIVATIVE; VASODILATOR AGENT;

APOPTOSIS; CARDIOMYOPATHY; CELL DEATH; CELL PROLIFERATION; CLINICAL FEATURE; DETERIORATION; FATALITY; FLUID RETENTION; HEART DEATH; HEART FAILURE; HEART HYPERTROPHY; HEART OUTPUT; HEART VENTRICLE OVERLOAD; HEART VENTRICLE REMODELING; HEMODYNAMICS; HUMAN; HYPERTENSION; MALADJUSTMENT; MORTALITY; PROGNOSIS; REVIEW; SIGNAL TRANSDUCTION; SURVIVAL RATE; VENOUS PRESSURE;

EID: 0141788787     PISSN: 15821838     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1582-4934.2003.tb00197.x     Document Type: Review

References (83)

1. Katz A.M., Heart Failure: Pathophysiology, Molecular Biology, and Clinical Management. Philadelphia, Lippincott/Williams & Wilkins, 2000
2. Ross J. Jr., Afterload mismatch and preload reserve: a conceptual framework for the analysis of ventricular function, Prog. Cardiovasc. Dis., 18:255-264, 1976
3. Packer M., Cohn J.N., Consensus recommendations for the management of heart failure, Am. J. Cardiol., 83(Suppl 2a):1A-38A, 1999
4. Cohn J.N., Archibald D.G., Ziesche S., Franciosa J.A., Harston W.E., Tristani F.E., Dunkman W.B., Jacobs W., Francis G.S., Cobb F.R., Shah P.M., Saunders R., Fletcher R.D., Loeb H.S., Hughes V.C., Baker B., Effect of vasodilator therapy on mortality in chronic congestive heart failure. Results of a Veterans Administration cooperative study(V-HeFT), New Eng. J. Med., 314:1547-52, 1986
5. Cohn J.N., Introduction. The Vasodilator-Heart Failure Trials (V-HeFT). Mechanistic studies from the VA cooperative studies, Circulation, 87(Suppl VI):VI-1-VI-4, 1993
6. Franciosa J.A., Jordon R.A., Wilen M.M., Leddy C.L., Minoxidil in patients with chronic left heart failure. Contrasting hemodynamic and clinical effects in a controlled trial, Circulation, 70:63-38, 1984
7. Elkayam U., Amin J., Mehra A., Vasquez J., Weber L., Rahimtoola S.H., A prospective, randomized, double-blind, crossover study to compare the efficacy and safety of chronic nifedipine therapy with that of isosorbide dinitrate and their combination in the treatment of congestive heart failure, Circulation, 82:1954-1961, 1990
8. Goldstein R.E., Boccuzzi S.J., Cruess D., Nattel S., The Adverse Experience Committee, and the Multicenter Diltiazem Postinfarction Research Group. Diltiazem increases late-onset congestive heart failure in postinfarction patients with early reduction in ejection fraction, Circulation, 83:52-60, 1991
9. CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure: Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS), New Eng. J. Med., 316:1429-35, 1987
10. The SOLVD Investigators. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fraction, New Eng. J. Med., 327:685-691, 1992
11. Pfeffer M.A., Braunwaid E., Moyé L.A., Basta L., Brown E.J. Jr, Cuddy T.E., Davis B.R., Geltman E.M., Goldman S., Flaker C.G., Klein M., Lamas G.A., Packer M., Rouleau J., Rouleau J.L., Rutherford J., Wertheimer J.H., Hawkins C.M., On behalf of the SAVE Investigators. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial, New Eng. J. Med., 327:669-677, 1992
12. Cotten M.DeV., Stopp P.E., The action of digitalis on the non-tailing heart of the dog, Am. J. Physiol., 192:114-120, 1958
13. Gazes P.C., Goldberg L.I., Darby T.D., Heart force effects of sympathomimetic amines as a basis for their use shock accompanying myocardial infarction, Circulation, 8:883-892, 1953
14. Benotti J.R., Grossman W., Braunwald E., Davolos D.D., Alousi A.A., Hemodynamic assessment of amrinone. A new inotropic agent, New Eng J. Med., 299:1373-1377, 1978
15. Bairn D.S., McDowell A.V., Cherniles J., Monrad E.S., Parker J.A., Edelson J., Braunwald E., Grossman W., Evaluation of a new bipyridine inotropic agent - milrinone - in patients with severe congestive heart failure, New Eng. J. Med., 309:748-756, 1983
16. Katz A.M., A new inotropic drug: Its promise and a caution, New Eng. J. Med., 299:1409-1410, 1978
17. Katz A.M., Potential deleterious effects of inotropic agents in the therapy of heart failure, Circulation, 73(Suppl III):184-190, 1986
18. Packer M., Leier C.V., Survival in congestive heart failure during treatment with drugs with positive inotropic actions, Circulation, 75(Suppl IV):IV-55-IV-63, 1987
19. Dies E, Krell M.J., Whitlow P., Liang C-s., Goldenberg I., Applefield M.M., et al. (Abstract) Intermittent dobutamine in ambulatory outpatients with chronic cardiac failure, Circulation, 74:II-38, 1986
20. Xamoterol in Severe Heart Failure Study Group. Xamoterol in severe heart failure, Lancet, 335:1-6, 1990
21. Yusuf S., Teo K., Inotropic agents increase mortality in patients with congestive heart failure, (Abstract) Circ., 82(Suppl III):III-673, 1990
22. Uretsky B.F., Jessup M., Konstam M.A., Dec G.W., Leier C.V., Benotti J., et al., for the Enoximone Multicenter Trial Group. Mulitcenter trial of oral enoximone in patients with moderate to moderately severe heart failure. Lack of benefit compared with placebo, Circulation, 82:774-478, 1990
23. Packer M., Carver J.R., Rodeheffer R.J., Ivanhoe R.J., DiBianco R., Zeldis S.M., Hendrix G.H., Bommer W.J., Elkayam U., Kukin M.L., Mallis G.I., Sollano J.A., Shannon J., Tandon P.K., DeMets D.L., Effect of oral milrinone on mortality in severe heart failure, New Engl. J. Med., 325:1468-1475, 1991
24. Pimobendan in Congestive Heart Failure (PICO) Investigators. Effect of pimobendan on exercise capacity in patients with heart failure; main results from the Pimobendan in Congestive Heart Failure (PICO) Trial, Heart, 76:223-231, 1996
25. Cohn J.N., Goldstein S.O., Greenberg B.H., Lorell B.H., Bourge R.C., Jaski B.E., Gottlieb S.O., McGrew F., Demets D.L., White B.G., A dose-dependent increase in mortality with vesnarinone among patients with severe heart failure, N. Engl. J. Med., 339:1810-1816, 1998
26. Felker G.M., O'Connor C.M., Inotropic therapy for heart failure: An evidence-based approach, Am. Heart J., 142:393-401, 2001
27. The Digitalis Investigation Group. The effect of digoxin on mortality and morbidity in patients with heart failure, New Engl. J. Med., 336:525-533, 1997
28. Francis G.S., Goldsmith S.R., Levine T.B., Olivari M.T., Cohn J.N., The neurohumoral axis in congestive heart failure, Ann. Int. Med., 101:370-377, 1984
29. Harris P., Evolution and the cardiac patient, Cardiovasc Res., 17:313-319, 373-378, 437-445, 1983
30. rd Ed. Philadelphia, Lippincott, 2001
31. Packer M., The neurohumoral hypothesis: a theory to explain the mechanism of disease progression in heart failure, J. Am. Coll. Cardiol., 20:248-254, 1992
32. Pitt B., Zannad F., Remme W.J., Cody R., Castaigne A., Perez A., Palensky J., Wittes J., for the Randomized Aldactone Evaluation Study Investigators. The effect of spironolactone on morbidity and mortality in patients with severe heart failure, New Engl. J. Med., 341:709-717, 1999
33. 2+ current in adult rat cardiomyocytes, Circ Res., 95:1139-1145, 1999
34. Zannad E, Alla F., Douset B., Perez A., Pitt B., on behalf of the RALES Investigators. Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure. Insights from the Randomized Aldactone Evaluation Study (RALES), Circulation, 102:2700-2706, 2000
35. Packer M., Bristow M.R., Cohn J.N., Colucci W.S., Fowler M.B., Gilbert E.M., Shusterman N.H., for the US Carvedilol Heart Failure Study Group, New Engl. J. Med., 334:1349-1355, 1996
36. LeChat P., Packer M., Chalon S., Cucherat M., Arab T., Boissel J.-P., Clinical effects of b-adrenergic blockade in chronic heart failure, Circulation, 98:1184-1191, 1998
37. CIBIS-II Investigators and Committees. The cardiac insufficiency bisoprolol study II (CIBIS-II): A randomised trial, Lancet, 353:9-13, 1999
38. Merit-HF Study Group. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL randomized intervention trial in congestive heart failure (MERIT-HF), Lancet, 353:2001-2007, 1999
39. Katz A.M., Cardiomyopathy of overload. A major determinant of prognosis in congestive heart failure, New Engl. J. Med., 322:100-110, 1990
40. Katz A.M., Evolving concepts of heart failure: cooling furnace, malfunctioning pump, enlarging muscle. Part I. Heart failure as a disorder of the cardiac pump, J. Cardiac Failure, 3:319-334, 1997
41. Katz A.M., Evolving Concepts of Heart Failure: Cooling Furnace, Malfunctioning Pump, Enlarging Muscle. Part II. Hypertrophy and dilatation of the failing heart, J. Cardiac Failure, 4:67-81, 1998
42. Katz A.M., Ernest Henry Starling, his predecessors, and the "Law of the Heart", Circulation, 106:2986-2992, 2002
43. Meerson F.Z., On the mechanism of compensatory hyper-function and insufficiency of the heart, Cor et Vasa, 3:161-177, 1961
44. Burch G.E., Ray C.T., Cronvick J.A., Certain mechanical peculiarities of the human cardiac pump in normal and diseased states, Circulation, 5:504-513, 1952
45. Burton A.C., Importance of the shape and size of the heart. Am. Heart J., 54:8011-801, 1957
46. Sandler H., Dodge H.T., Left ventricular tension and stress in man, Circ. Res., 13:91-104, 1963
47. Hood W.P. Jr., Rackley C.E., Rolett E.L., Wall stress in the normal and hypertrophied human left ventricle, Am. J. Cardiol., 22:5550-558, 1968
48. Grossman W., Jones D., McLaurin L.P., Wall stress and patterns of hypertrophy in the human left ventricle, J. Clin. Invest., 56:56-64, 1975
49. Hochman J.S., Bulkley B.H., Expansion of acute myocardial infarction: an experimental study, Circulation, 65:1446-1450, 1982
50. Weisman H.F., Bush D.E., Mannisi J.A., Bulkley B.H., Global cardiac remodeling after acute myocardial infarction: a study in the rat model, J. Am. Coll. Cardiol., 5:1355-1362, 1985
51. Erlebacher J.A., Ventricular remodeling in myocardial infarction - the rat and the human (letter), Am. J. Cardiol., 56:910, 1985
52. Pfeffer J.M., Pfeffer M.A., Braunwald E., Influence of chronic captopril therapy on the infarcted left ventricle of the rat, Circ. Res., 57:84-95, 1985
53. Pfeffer M.A., Pfeffer J.M., Steinberg C., Finn P., Survival after experimental myocardial infarction: beneficial effects of long term therapy with captopril, Circulation, 72:406-412, 1985
54. Pfeffer M.A., Lamas G.A., Vaughan D.E., Parisi A.F., Brannwald E., Effect of captopril on progressive left ventricular dilatation after anterior myocardial infarction, N. Engl. J. Med., 319:80-86, 1988
55. Sharpe N., Murphy J., Smith H., Hannan S., Treatment of patients with symptomless left ventricular dysfunction after myocardial infarction, Lancet, 1:255-259, 1988
56. Smith H., Hannan S., Preventive treatment of asymptomatic left ventricular dysfunction following myocardial infarction, Eur. Heart J., 11:S147-S156, 1990
57. Pfeffer M.A., Braunwald E., Ventricular remodeling after myocardial infarction: experimental observations and clinical implications, Circulation, 81:1161-1172, 1990
58. Sharpe N., Smith H., Murphy J., Greaves S., Hart H., Gamble G., Early prevention of left ventricular dysfunction after myocardial infarction with angiotensin converting-enzyme inhibition, Lancet, 337:872-876, 1991
59. Oldroyd K.G., Pye M.P., Ray S.G., Christie J., Ford I., Cobbe S.M., Dargie H.J., Effects of early captopril administration on infarct expansion, left ventricular remodeling and exercise capacity after acute myocardial infarction, Am. J. Cardiol., 68:713-718, 1991
60. Mitchell G.F., Lamas G.A., Vaughan D.E., Pfeffer M.A., Left ventricular remodeling in the year after first anterior myocardial infarction: a quantitative analysis of contractile segment lengths and ventricular shape, J. Am. Coll. Cardiol., 19:1136-1144, 1992
61. Spann J.F. Jr., Buccino R.A., Sonnenblick E.H., Braunwald E., Contractile state of cardiac muscle obtained from cats with experimentally produced ventricular hypertrophy and heart failure, Circ. Res., 21:341-354, 1967
62. Katz A.M., Congestive heart failure: Role of altered myocardial cellular control, New Engl. J. Med., 293:1184-1191, 1975
63. Pfeffer J.M., Pfeffer M.A., Braunwald E., Influence of chronic captopril therapy on the infarcted left ventricle of the rat, Circ. Res., 57:84-95, 1985
64. Pfeffer M.A., Pfeffer J.M., Steinberg C., Finn P., Survival after experimental myocardial infarction: beneficial effects of long-term therapy with captopril, Circulation, 72:406-412, 1985
65. Pfeffer M.A., Lamas G.A., Vaughan D.E., Parisi A.F., Braunwald E., Effect of captopril on progressive left ventricular dilatation after anterior myocardial infarction, N. Engl. J. Med., 319:80-86, 1988
66. Sharpe N., Murphy J., Smith H., Hannan S., Treatment of patients with symptomless left ventricular dysfunction after myocardial infarction, Lancet, 1:255-259, 1988
67. Smith H., Hannan S., Preventive treatment of asymptomatic left ventricular dysfunction following myocardial infarction, Eur. Heart J., 11:S147-S156, 1990
68. Pfeffer M.A., Braunwald E., Ventricular remodeling after myocardial infarction: experimental observations and clinical implications, Circulation, 81:1161-1172, 1990
69. Sharpe N., Smith H., Murphy J., Greaves S., Hart H., Gamble G., Early prevention of left ventricular dysfunction after myocardial infarction with angiotensin converting-enzyme inhibition, Lancet, 337:872-876, 1991
70. Oldroyd K.G., Pye M.P., Ray S.G., Christie J., Ford I., Cobbe S.M., Dargie H.J., Effects of early captopril administration on infarct expansion, left ventricular remodeling and exercise capacity after acute myocardial infarction, Am. J. Cardiol., 68:713-718, 1991
71. Mitchell G.F., Lamas G.A., Vaughan D.E., Pfeffer M.A., Left ventricular remodeling in the year after first anterior myocardial infarction: a quantitative analysis of contractile segment lengths and ventricular shape, J. Am. Coll. Cardiol., 19:1136-1144, 1992
72. Hayashida W., van Eyll C., Rousseau H.F., Pouleur H., for the SOLVD Investigators. Regional remodeling and nonuniform changes in diastolic function in patients with left ventricular dysfunction: Modification by long-term enalapril treatment, J. Am. Coll. Cardiol., 22:1403-1410, 1993
73. McDonald K.M., Rector T., Carlyle P.F., Francis G.S., Cohn J.N., Angiotensin-converting enzyme inhibition and beta-adrenoreceptor blockade regress established ventricular remodeling in a canine model of discrete myocardial damage, J. Am. Coll. Cardiol., 24:1762-1768, 1994
74. St John Sutton M., Pfeffer M.A., Moye L., Plappert T., Rouleau J.L., Lamas G., Rouleau J., Parker J.O., Arnold M.O., Sussex B., Braunwald E., for the SAVE Investigators. Cardiovascular death and left ventricular remodeling two years after myocardial infarction: baseline predictors and impact of long-term use of captopril: information from the survival and ventricular enlargement (SAVE) trial, Circulation, 96:3294-3299, 1997
75. Greenberg B., Quinones M.A., Koilpillai C., Limacher M., Schindler D., Benedict C., Shelton B., for the SOLVD Investigators. Effects of long-term enalapril therapy on cardiac structure and function in patients with left ventricular dysfunction. Results of the SOLVD echocardiography substudy, Circulation, 91:2573-2581, 1995
76. Hall S.A., Cigarroa C.G., Marcoux L., Risser R.C., Grayburn P.A., Eichhorn E.J., Time course of improvement in left ventricular function, mass and geometry in patients with congestive heart failure treated with beta-adrenergic blockade, J. Am. Coll. Cardiol., 25:1154-1161, 1995
77. Doughty R.N., Whalley G.A., Gamble G., MacMahon S., Sharpe N., on behalf of the Australia-New Zealand Heart Failure Research Collaborative Group. Left ventricular remodeling with carvedilol in patients with congestive heart failure due to ischemic heart disease, J. Am. Coll. Cardiol., 29:1060-1066, 1997
78. Basu S., Senior R., Raval U., van der Does R., Bruckner T., Lahiri A., Beneficial effects of intravenous and oral carvedilol treatment in acute myocardial infarction. A placebo-controlled randomized trial, Circulation, 96:183-191, 1997
79. Lowes B.D., Gill E.A., Abraham W.T., Larrain J.R., Robertson A.D., Bristow M.R., Gilbert E.M., Effects of carvedilol on left ventricular mass, chamber geometry, and mitral regurgitation in chronic heart failure, Am. J. Cardiol., 83:1201-1205, 1999
80. Senior R., Basu S., Kinsey C., Schaeffer S., Lahiri A., Carvedilol prevents remodeling in patients with left ventricular dysfunction following acute myocardial infarction, Am. Heart J., 137:646-652, 1999
81. Ricci R., Coletta C., Ceci V., Pajes G., Putini R.L., Salustri A., Bottero G., Pasquale M., on behalf of the RIMA Researchers. Effect of early treatment with captopril and metoprolol singly and together on postinfarction left ventricular remodeling, Am. Heart J., 142:e5, 2001
82. Khattar R.S., Senior R., Soman P., van der Does R., Lahiri A., Regression of left ventricular remodeling in chronic heart failure: Comparative and combined effects of captopril and carvedilol, Am. Heart. J., 142:704-713, 2001
83. Katz A.M., Crossovers between functional and proliferative signaling: key to understanding the pathophysiology and management of heart failure, J. Cell. Mol. Med., 5:125-131, 2001